S&P 500   3,117.43 (+0.15%)
DOW   27,677.79 (+0.10%)
QQQ   202.43 (+0.51%)
AAPL   265.58 (+1.47%)
FB   199.36 (+0.33%)
MSFT   149.93 (+0.05%)
GOOGL   1,326.96 (+0.61%)
AMZN   1,740.48 (-1.15%)
CGC   18.60 (+1.20%)
NVDA   208.74 (-0.32%)
MU   46.62 (+0.69%)
BABA   200.00 (+3.23%)
GE   10.79 (-1.01%)
TSLA   330.37 (-0.80%)
T   38.19 (+0.24%)
AMD   39.62 (-0.18%)
ACB   2.44 (-1.61%)
F   8.93 (-0.22%)
PRI   134.30 (+0.83%)
NFLX   302.86 (-0.48%)
BAC   33.09 (-0.18%)
GILD   65.93 (-1.23%)
DIS   147.44 (-0.57%)
S&P 500   3,117.43 (+0.15%)
DOW   27,677.79 (+0.10%)
QQQ   202.43 (+0.51%)
AAPL   265.58 (+1.47%)
FB   199.36 (+0.33%)
MSFT   149.93 (+0.05%)
GOOGL   1,326.96 (+0.61%)
AMZN   1,740.48 (-1.15%)
CGC   18.60 (+1.20%)
NVDA   208.74 (-0.32%)
MU   46.62 (+0.69%)
BABA   200.00 (+3.23%)
GE   10.79 (-1.01%)
TSLA   330.37 (-0.80%)
T   38.19 (+0.24%)
AMD   39.62 (-0.18%)
ACB   2.44 (-1.61%)
F   8.93 (-0.22%)
PRI   134.30 (+0.83%)
NFLX   302.86 (-0.48%)
BAC   33.09 (-0.18%)
GILD   65.93 (-1.23%)
DIS   147.44 (-0.57%)
S&P 500   3,117.43 (+0.15%)
DOW   27,677.79 (+0.10%)
QQQ   202.43 (+0.51%)
AAPL   265.58 (+1.47%)
FB   199.36 (+0.33%)
MSFT   149.93 (+0.05%)
GOOGL   1,326.96 (+0.61%)
AMZN   1,740.48 (-1.15%)
CGC   18.60 (+1.20%)
NVDA   208.74 (-0.32%)
MU   46.62 (+0.69%)
BABA   200.00 (+3.23%)
GE   10.79 (-1.01%)
TSLA   330.37 (-0.80%)
T   38.19 (+0.24%)
AMD   39.62 (-0.18%)
ACB   2.44 (-1.61%)
F   8.93 (-0.22%)
PRI   134.30 (+0.83%)
NFLX   302.86 (-0.48%)
BAC   33.09 (-0.18%)
GILD   65.93 (-1.23%)
DIS   147.44 (-0.57%)
S&P 500   3,117.43 (+0.15%)
DOW   27,677.79 (+0.10%)
QQQ   202.43 (+0.51%)
AAPL   265.58 (+1.47%)
FB   199.36 (+0.33%)
MSFT   149.93 (+0.05%)
GOOGL   1,326.96 (+0.61%)
AMZN   1,740.48 (-1.15%)
CGC   18.60 (+1.20%)
NVDA   208.74 (-0.32%)
MU   46.62 (+0.69%)
BABA   200.00 (+3.23%)
GE   10.79 (-1.01%)
TSLA   330.37 (-0.80%)
T   38.19 (+0.24%)
AMD   39.62 (-0.18%)
ACB   2.44 (-1.61%)
F   8.93 (-0.22%)
PRI   134.30 (+0.83%)
NFLX   302.86 (-0.48%)
BAC   33.09 (-0.18%)
GILD   65.93 (-1.23%)
DIS   147.44 (-0.57%)
Log in

NASDAQ:KITE - Kite Pharma Stock Price, Forecast & News

Notice: This company has been marked as potentially delisted and may not be actively trading.
Add
Today's Range N/A
50-Day Range N/A
52-Week Range N/A
VolumeN/A
Average Volume1.65 million shs
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Kite Pharma, Inc is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of cancer immunotherapy products to target and kill cancer cells. The Company offers engineered autologous cell therapy, which is an approach to the treatment of cancer. Its therapy involves modifying a patient's T cells outside the patient's body, or ex vivo, causing the T cells to express chimeric antigen receptors (CARs), or T cell receptors (TCRs), and then reinfusing the engineered T cells back into the patient. Read More…

Industry, Sector and Symbol

Industry N/A
Sub-IndustryN/A
SectorN/A
Current SymbolNASDAQ:KITE
CUSIPN/A
Phone+1-310-8249999

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

EmployeesN/A
Next Earnings DateN/A
OptionableOptionable

Receive KITE News and Ratings via Email

Sign-up to receive the latest news and ratings for KITE and its competitors with MarketBeat's FREE daily newsletter.


Kite Pharma (NASDAQ:KITE) Frequently Asked Questions

What is Kite Pharma's stock symbol?

Kite Pharma trades on the NASDAQ under the ticker symbol "KITE."

How were Kite Pharma's earnings last quarter?

Kite Pharma Inc (NASDAQ:KITE) announced its earnings results on Tuesday, February, 28th. The biopharmaceutical company reported ($1.70) earnings per share for the quarter, beating analysts' consensus estimates of ($1.75) by $0.05. The biopharmaceutical company had revenue of $4.90 million for the quarter, compared to analysts' expectations of $5.74 million. Kite Pharma's quarterly revenue was up .0% on a year-over-year basis. During the same quarter in the prior year, the firm posted ($0.54) earnings per share. View Kite Pharma's Earnings History.

Has Kite Pharma been receiving favorable news coverage?

News articles about KITE stock have trended somewhat positive on Thursday, according to InfoTrie. InfoTrie identifies positive and negative news coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. Kite Pharma earned a media sentiment score of 1.7 on InfoTrie's scale. They also assigned media coverage about the biopharmaceutical company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an effect on the company's share price in the immediate future. View News Stories for Kite Pharma.

What other stocks do shareholders of Kite Pharma own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Kite Pharma investors own include Puma Biotechnology (PBYI), Medivation (MDVN), BioMarin Pharmaceutical (BMRN), Incyte (INCY), First Solar (FSLR), Dynavax Technologies (DVAX), United Continental (UAL), Juno Therapeutics (JUNO), bluebird bio (BLUE) and Array Biopharma (ARRY).

Who are Kite Pharma's key executives?

Kite Pharma's management team includes the folowing people:
  • Arie S. Belldegrun, Executive Chairman of the Board, President, Chief Executive Officer, Founder
  • Paul L. Jenkinson, Chief Financial Officer
  • Cynthia M. Butitta, Chief Operating Officer
  • David Chang M.D. Ph.D., Executive Vice President - Research and Development, Chief Medical Officer
  • Helen S. Kim, Executive Vice President - Business Development
  • Timothy L. Moore, Executive Vice President - Technical Operations
  • Christine Cassiano, Senior Vice President - Corporate Communications and Investor Relations
  • , Bio & Compensation - 
  • Jian Irish Ph.D., Senior Vice President - Supply Chain
  • , Bio & Compensation - 
  • Jeffrey Wiezorek M.D., Senior Vice President - Clinical Development
  • Shawn Cline Tomasello, Chief Commercial Officer

What is Kite Pharma's official website?

The official website for Kite Pharma is http://www.kitepharma.com/.

How can I contact Kite Pharma?

Kite Pharma's mailing address is 2225 Colorado Ave, SANTA MONICA, CA 90404-3505, United States. The biopharmaceutical company can be reached via phone at +1-310-8249999.


MarketBeat Community Rating for Kite Pharma (NASDAQ KITE)

Community Ranking:  3.3 out of 5 (star star star)
Outperform Votes:  734 (Vote Outperform)
Underperform Votes:  365 (Vote Underperform)
Total Votes:  1,099
MarketBeat's community ratings are surveys of what our community members think about Kite Pharma and other stocks. Vote "Outperform" if you believe KITE will outperform the S&P 500 over the long term. Vote "Underperform" if you believe KITE will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 12/5/2019 by MarketBeat.com Staff

Featured Article: Percentage Decliners

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel